Core Technology
Versadel is Ablitech's core technology.
This nucleic acid therapeutic platform has the potential to treat a number of diseases and enable the multi-billion dollar RNAi therapeutics market.
Versadel works by using very selective chemistry to attach a hydrophilic polymer to a nucleic acid (antisense DNA or siRNA).
The polymer protects the nucleic acid by creating a thin shell around it until it is safely delivered inside of a cell.
Once inside the cell the chemisty reverses and the nucleic acid is released from the polymer.
The polymer is safely cleared from the body as the nucleic acid begins interfering with the production of disease-causing proteins.
 Click here to download the Versadel Primer PDF.
|
